Impact of Copy Neutral Loss of Heterozygosity and Total Genome Aberrations on Survival in Myelodysplastic Syndrome

[1]  P. Nguyen,et al.  Myelodysplastic syndromes , 2009, Nature Reviews Disease Primers.

[2]  Mario Cazzola,et al.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.

[3]  Z. Zemanová,et al.  Copy number neutral loss of heterozygosity at 17p and homozygous mutations of TP53 are associated with complex chromosomal aberrations in patients newly diagnosed with myelodysplastic syndromes. , 2016, Leukemia research.

[4]  F. Solé,et al.  Impact of SNP array karyotyping on the diagnosis and the outcome of chronic myelomonocytic leukemia with low risk cytogenetic features or no metaphases , 2016, American journal of hematology.

[5]  S. Ogawa,et al.  Array CGH identifies copy number changes in 11% of 520 MDS patients with normal karyotype and uncovers prognostically relevant deletions , 2016, Leukemia.

[6]  U. Platzbecker,et al.  Influence of total genomic alteration and chromosomal fragmentation on response to a combination of azacitidine and lenalidomide in a cohort of patients with very high risk MDS. , 2015, Leukemia research.

[7]  R. Gibbs,et al.  The relationship of JAK2V617F and acquired UPD at chromosome 9p in polycythemia vera , 2014, Leukemia.

[8]  T. Haferlach,et al.  Investigation of 305 patients with myelodysplastic syndromes and 20q deletion for associated cytogenetic and molecular genetic lesions and their prognostic impact , 2014, British journal of haematology.

[9]  Renato Martins,et al.  Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimens. , 2014, The Journal of molecular diagnostics : JMD.

[10]  C. Morris,et al.  Polyploidy in myelofibrosis: analysis by cytogenetic and SNP array indicates association with advancing disease , 2013, Molecular Cytogenetics.

[11]  L. Arenillas,et al.  Single nucleotide polymorphism array karyotyping: A diagnostic and prognostic tool in myelodysplastic syndromes with unsuccessful conventional cytogenetic testing , 2013, Genes, chromosomes & cancer.

[12]  A. Giagounidis,et al.  Morphology, cytogenetics and classification of MDS. , 2013, Best practice & research. Clinical haematology.

[13]  J. C. Williamson,et al.  Current pathology practices in and barriers to MDS diagnosis. , 2013, Leukemia research.

[14]  N. Mounier,et al.  Total genomic alteration as measured by SNP-array-based molecular karyotyping is predictive of overall survival in a cohort of MDS or AML patients treated with azacitidine , 2013, Blood Cancer Journal.

[15]  H. Deeg,et al.  Hematopoietic stem cell transplantation for older patients with myelodysplastic syndromes. , 2013, Journal of the National Comprehensive Cancer Network : JNCCN.

[16]  G. Raca,et al.  The advantage of using SNP array in clinical testing for hematological malignancies--a comparative study of three genetic testing methods. , 2013, Cancer genetics.

[17]  S. Gore,et al.  Myelodysplastic syndromes: what do hospitalists need to know? , 2013, Journal of hospital medicine.

[18]  J. Huh,et al.  Different characteristics identified by single nucleotide polymorphism array analysis in leukemia suggest the need for different application strategies depending on disease category , 2013, Genes, chromosomes & cancer.

[19]  L. Shaffer,et al.  The use of cytogenetic microarrays in myelodysplastic syndrome characterization. , 2013, Methods in molecular biology.

[20]  Z. Zemanová,et al.  From cryptic chromosomal lesions to pathologically relevant genes: Integration of SNP‐array with gene expression profiling in myelodysplastic syndrome with normal karyotype , 2012, Genes, chromosomes & cancer.

[21]  B. Wood,et al.  Prognostic impact of discordant results from cytogenetics and flow cytometry in patients with acute myeloid leukemia undergoing hematopoietic cell transplantation , 2012, Cancer.

[22]  H. Deeg,et al.  Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome: Current Status , 2011, Archivum Immunologiae et Therapiae Experimentalis.

[23]  J. Vardiman,et al.  World health organization classification, evaluation, and genetics of the myeloproliferative neoplasm variants. , 2011, Hematology. American Society of Hematology. Education Program.

[24]  C. O'keefe,et al.  SNP array-based karyotyping: differences and similarities between aplastic anemia and hypocellular myelodysplastic syndromes. , 2011, Blood.

[25]  M. McDevitt,et al.  Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies. , 2011, Blood.

[26]  David D. Smith,et al.  Assessing karyotype precision by microarray-based comparative genomic hybridization in the myelodysplastic/myeloproliferative syndromes , 2010, Molecular Cytogenetics.

[27]  Michael A McDevitt,et al.  Copy neutral loss of heterozygosity: a novel chromosomal lesion in myeloid malignancies. , 2010, Blood.

[28]  J. Vardiman,et al.  The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues: an overview with emphasis on the myeloid neoplasms. , 2010, Chemico-biological interactions.

[29]  S. Kash,et al.  Array-based karyotyping for prognostic assessment in chronic lymphocytic leukemia: performance comparison of Affymetrix 10K2.0, 250K Nsp, and SNP6.0 arrays. , 2010, The Journal of molecular diagnostics : JMD.

[30]  C. O'keefe,et al.  Use of SNP-array-based karyotyping for cytogenetic prognostication in unclassified cases of myelodysplasia and associated overlap disorders. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  C. Bloomfield,et al.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.

[32]  Jungwon Huh,et al.  Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. , 2009, Blood.

[33]  M. Loh,et al.  Accurate Detection of Uniparental Disomy and Microdeletions by SNP Array Analysis in Myelodysplastic Syndromes with Normal Cytogenetics , 2009, Leukemia.

[34]  M. McDevitt,et al.  250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies. , 2008, Cancer research.

[35]  C. O'keefe,et al.  Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. , 2008, Blood.

[36]  Thomas H Müller,et al.  New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. , 2007, Blood.

[37]  G. Mufti,et al.  Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes. , 2007, Blood.

[38]  Å. Borg,et al.  High-resolution genome-wide array-based comparative genome hybridization reveals cryptic chromosome changes in AML and MDS cases with trisomy 8 as the sole cytogenetic aberration , 2006, Leukemia.

[39]  Jean McGowan-Jordan,et al.  ISCN 2013 : an international system for human cytogenetic nomenclature (2013) : recommendations of the International Standing Committee on Human Cytogenetic Nomenclature , 2005 .

[40]  D. Oscier,et al.  Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. , 2005, Blood.

[41]  B. Wood,et al.  Ten‐Color Immunophenotyping of Hematopoietic Cells , 2005, Current protocols in cytometry.

[42]  Mario Cazzola,et al.  A gain-of-function mutation of JAK2 in myeloproliferative disorders. , 2005, The New England journal of medicine.

[43]  E. Estey,et al.  Cytogenetic evolution following the transformation of myelodysplastic syndrome to acute myelogenous leukemia: implications on the overlap between the two diseases. , 1994, Leukemia.